PI3 kinase as a therapeutic target for diseases associated with mutations in the catalytic domain of Kit.

被引：0
|
作者：
Linnekin, D [1 ]
Krupa, S [1 ]
机构：
[1] NCI, Frederick Canc Res Facil, Basic Res Lab, Frederick, MD USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
712
引用
收藏
页码：190A / 190A
页数：1
相关论文
共 50 条
  • [31] Hedgehog Pathway Inhibition Is a Novel Therapeutic Approach in Lymphomas and Its Efficacy is Inversely Related to PI3 Kinase Inhibition
    Walsh, Katherine J.
    Fan, Siyao
    Patel, Amee
    Jacobs, Cassandra L.
    Smith, Jason
    Liu, Qingquan
    Dave, Sandeep
    BLOOD, 2010, 116 (21) : 770 - 770
  • [32] Stem cell factor (SCF)-Kit mediated phosphatidylinositol 3 (PI3) kinase signaling during mammalian oocyte growth and early follicular development
    Liu, K
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 : 126 - 135
  • [33] Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies
    Bursavich, Matthew G.
    Brooijmans, Natasja
    Feldberg, Lawrence
    Hollander, Irwin
    Kim, Stephen
    Lombardi, Sabrina
    Park, Kaapjoo
    Mallon, Robert
    Gilbert, Adam M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (08) : 2586 - 2590
  • [34] Evidence for Initial Non-specific Polypeptide Chain Collapse During the Refolding of the SH3 Domain of PI3 Kinase
    Dasgupta, Amrita
    Udgaonkar, Jayant B.
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 403 (03) : 430 - 445
  • [35] Phosphatidylinositol 3-kinase (PI3K) pathway - A therapeutic target for human glioblastoma
    Koul, Dimpy
    Shen, Ruijun
    Edge, Jennifer
    Liu, T. J.
    Powis, Garth
    Lynn Kirkpatrick, D.
    Alfred Yung, W. K.
    NEURO-ONCOLOGY, 2006, 8 (04) : 414 - 414
  • [36] Revealing a Concealed Intermediate that Forms after the Rate-limiting Step of Refolding of the SH3 Domain of PI3 Kinase
    Wani, Ajazul Hamid
    Udgaonkar, Jayant B.
    JOURNAL OF MOLECULAR BIOLOGY, 2009, 387 (02) : 348 - 362
  • [37] Importance of PI3 kinase family for crosstalk between chronic lymphocytic leukemia B cells and the stromal microenvironment: Therapeutic implications
    Niedermeier, Matthias T. W.
    Rawluk, Justyna
    Knight, Zachary
    Shokat, Kevan
    Wierda, William G.
    Keating, Michael J.
    Burger, Jan A.
    BLOOD, 2007, 110 (11) : 341A - 341A
  • [38] Spotlight: Emilio Hirsch, PhD, FESC Aiming to Prove the Benefits of Treating Some Cardiac Diseases With PI3 Kinase γ Inhibitors
    Taylor, Jennifer
    Hirsch, Emilio
    CIRCULATION, 2009, 119 (12) : F67 - F69
  • [39] Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: Might c-kit represent a therapeutic target?
    Giantin, M.
    Aresu, L.
    Arico, A.
    Gelain, M. E.
    Riondato, F.
    Comazzi, S.
    Dacasto, M.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2013, 154 (3-4) : 153 - 159
  • [40] Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: Might c-KIT represent a therapeutic target?
    Giantin, M.
    Aresu, L.
    Arico, A.
    Gelain, M. E.
    Riondato, F.
    Martini, V.
    Comazzi, S.
    Dacasto, M.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2013, 152 (3-4) : 325 - 332
12345